Drugs / ch806
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00291447 | May 2005 → Feb 2006 | neoplasm | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ch806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00291447 ↗ |
| Known as | 111In-ch806 | “tagged with a trace amount of radioactive 111-Indium: 111In-ch806” NCT00291447 ↗ |
| Modality | Monoclonal antibody | “specially constructed monoclonal antibody (mAB) called "ch806"” NCT00291447 ↗ |
| Route | Intravenous | “111In-ch806 is given by infusion into a vein over one hour” NCT00291447 ↗ |
| Target | EGFR | “a protein called the 806 antigen (a type of EGFR)” NCT00291447 ↗ |